PDS Biotechnology Corp — Director's Dealing 2017

Nov 3, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2017-11-01

Reporting Person: Saik Andrew (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-11-01	Stock Option (Right To Purchase)	$10.73	A	200000	Acquired	2027-11-01	Common Stock (200000)	Direct

Footnotes

F1: This option, representing a right to purchase a total of 200,000 shares of Common Stock, will become exercisable on October 31, 2018, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date.